Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin: 2009-2025

Historic EBT Margin for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to 14.15%.

  • Aytu Biopharma's EBT Margin rose 511.00% to 14.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -20.85%, marking a year-over-year decrease of 1865.00%. This contributed to the annual value of -20.71% for FY2025, which is 478.00% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's EBT Margin is 14.15%, which was up 111.01% from -128.46% recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's EBT Margin registered a high of 20.69% during Q1 2025, and its lowest value of -220.22% during Q1 2022.
  • For the 3-year period, Aytu Biopharma's EBT Margin averaged around -16.94%, with its median value being -7.99% (2023).
  • As far as peak fluctuations go, Aytu Biopharma's EBT Margin plummeted by 12,345bps in 2021, and later skyrocketed by 18,855bps in 2023.
  • Quarterly analysis of 5 years shows Aytu Biopharma's EBT Margin stood at -49.95% in 2021, then soared by 2,448bps to -25.47% in 2022, then soared by 3,293bps to 7.46% in 2023, then slumped by 511bps to 2.35% in 2024, then surged by 511bps to 14.15% in 2025.
  • Its EBT Margin stands at 14.15% for Q3 2025, versus -128.46% for Q2 2025 and 20.69% for Q1 2025.